In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Insight Article
Erin Newburn, Senior Director, Field Applications Scientist at Personalis, Inc. showcases the Personalis NeXT Platform ®, a tumour profiling solution for both tissue and liquid biopsies at Biomarkers UK 2022.
Edited by Tia Byer |
04 July 2022
Biomarker Technologies
Discussion Group Report
Anna Lyubetskaya, Senior Principal Scientist at Bristol Myers Squibb, leads a discussion on the industry landscape and ‘Current Status of Omics-Based Biomarkers.’
Edited by Tia Byer |
30 June 2022
Genomic Markers & Precision Medicine
Commentary
Quantitative mass spectrometry offers a clinical tool for the discovery of biomarkers, which can be vital in helping to treat certain cancers. In this Commentary article, we explore the applications of mass spectrometry for the identification of triple negative breast cancer and some of the implications for future research.
27 June 2022
Biomarkers for Clinical Development
Insight Article
Senior representatives from Ultivue, Genentech, and GSK discuss the current trends and opportunities in enabling the future of multi-omics-based analysis.
Edited by Tia Byer |
24 June 2022
Biomarker Technologies
Discussion Group Report
Yu Liang, Director of Clinical Biomarkers at Compugen, leads a discussion on ‘Spatial Biomarkers & Multiplexed Immunofluorescence in Immuno-Oncology.’
Edited by Tia Byer |
25 May 2022
Biomarker Technologies
Insight Article
From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.
Edited by Tia Byer |
16 May 2022
Biomarkers for Drug Discovery & Development
Insight Article
Key opinion leaders from GlaxoSmithKline and Weill Cornell Medicine discuss future perspectives on neuro-organoids.
Edited by Tia Byer |
29 April 2022
Biomarkers for Clinical Development
Discussion Group Report
Jordi Clarimon, Lead Specialist in Fluid Biomarkers at Lundbeck, leads a discussion on ‘Fluid Biomarkers for Neurodegenerative Diseases.'
Edited by Tia Byer |
26 April 2022
Biomarkers for Clinical Development
Commentary
In this Commentary article, we investigate the applications of human stem cell modelling for identifying the ways in which neurodegenerative diseases such as Alzheimer's and Parkinson's affect the brain.
Edited by Ben Norris |
08 April 2022
Diagnostics
Commentary
This Commentary article explores the applications of pathway mining for the identification of disease targets associated with breast cancer, where there is an unmet need for treatment. The mission is to identify the best proliferation marker for guiding the choice of systemic treatments for breast cancer.
Edited by Ben Norris |
31 March 2022
Digital Biomarkers & Digital Pathology
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Translational Biomarkers to Guide Clinical Development of CAR T-Cells’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
31 March 2022
Biomarkers for Clinical Development
Insight Article
Data management for diagnostic devices is fast becoming a vital concern of the biomarkers industry. With the increased prevalence of ML and AI, this article interviews key opinion leaders from Nottingham Trent University, Apis Assay Technologies, and UCB about the future perspectives of diagnostic innovation and regulation.
Edited by Tia Byer |
30 March 2022
Diagnostics
Commentary
Looking at how Ultivue uses spatial imaging to observe biomarkers
10 March 2022
Biomarker Technologies
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group, focusing on ‘Using Biomarkers For Clinical Development & Regulatory Approval,’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
28 February 2022
Biomarkers for Clinical Development
Insight Article
How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.
Edited by Tia Byer |
25 February 2022
Biomarkers for Clinical Development
Commentary
Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.
Edited by Tom Cohen |
21 February 2022
Biomarkers for Clinical Development
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a select group of like-minded experts on a monthly basis. Our first Biomarkers Discussion Group addressing ‘Implementing Flow Cytometry Assays In Biomarker Research’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
31 January 2022
Biomarker Technologies
Commentary
This commentary article looks at the latest applications in digital and wearable biomarkers, with industry and academic insights from GlaxoSmithKline, Roche, and University College London.
Edited by Tia Byer |
26 January 2022
Digital Biomarkers & Digital Pathology
Commentary
Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints.
Edited by Tom Cohen |
19 January 2022
Digital Biomarkers & Digital Pathology
Insight Article
How do we implement the next generation of precision medicines and therapies to optimise patient experience? We sat down with senior representatives from Novartis, Merus, Labcorp, and Simcere Pharmaceuticals to discover the latest industry insights.
Edited by Tia Byer |
09 December 2021
Genomic Markers & Precision Medicine
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login